NAPLS Omega-3 Fatty Acid Versus Placebo Study

PHASE1CompletedINTERVENTIONAL
Enrollment

127

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

June 30, 2016

Study Completion Date

June 30, 2016

Conditions
Psychosis
Interventions
DRUG

Omega-3 Long Chain Fatty Acid

: The Omega-3FA compound will be manufactured by Ocean Nutrition Canada and contain an 2:1 proportion of EPA to DHA in which each capsule includes 370 mg EPA and 200 mg DHA as well as 2 mg/g Tocopherol. The dose will be two capsules per day for a total of 740 mg of EPA and 400 mg of DHA.

DRUG

Placebo

The placebo is a soybean/corn blend. Both the Omega-3FA and placebo are colored with carob (so shell is brown) and flavored with natural lemon-lime, to mask them. The dose will be 2 capsules per day.

Trial Locations (9)

11004

Zucker Hillside Hospital, Glen Oaks

15206

VA Pittsburgh Healthcare System, Pittsburgh

27599

University of North Carolina, Chapel Hill

30322

Emory University, Atlanta

90095

University of California, Los Angeles, Los Angeles

92093

University of California, San Diego, San Diego

06519

Yale University, New Haven

02215

Harvard, Boston

T2N 1N4

University of Calgary, Calgary

All Listed Sponsors
collaborator

National Institute of Mental Health (NIMH)

NIH

lead

University of California, San Diego

OTHER

NCT01429454 - NAPLS Omega-3 Fatty Acid Versus Placebo Study | Biotech Hunter | Biotech Hunter